DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
66	IgA腎症	2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02112838 (ClinicalTrials.gov)	October 2014	10/4/2014	Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy	A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy	IGA Nephropathy	Drug: Fostamatinib 150 mg;Drug: Fostamatinib 100 mg;Drug: Placebo	Rigel Pharmaceuticals	NULL	Completed	18 Years	70 Years	All	76	Phase 2	United States;Austria;Germany;Hong Kong;Taiwan;United Kingdom;Singapore;Switzerland
2	EUCTR2014-000331-16-AT (EUCTR)	25/08/2014	22/07/2014	N/A	A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy - N/A	IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Product Name: Fostamatinib 100 mg tablet Product Code: R935788 INN or Proposed INN: Fostamatinib Other descriptive name: FOSTAMATINIB DISODIUM Product Name: Fostamatinib 150 mg tablet Product Code: R935788 INN or Proposed INN: Fostamatinib Other descriptive name: FOSTAMATINIB DISODIUM	Rigel Pharmaceuticals Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	75	Phase 2	United States;Hong Kong;Taiwan;Singapore;Austria;United Kingdom;Switzerland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02112838
(ClinicalTrials.gov)

October 2014

10/4/2014

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy

IGA Nephropathy

Drug: Fostamatinib 150 mg;Drug: Fostamatinib 100 mg;Drug: Placebo

Rigel Pharmaceuticals

NULL

Completed

18 Years

70 Years

All

Phase 2

United States;Austria;Germany;Hong Kong;Taiwan;United Kingdom;Singapore;Switzerland

EUCTR2014-000331-16-AT
(EUCTR)

25/08/2014

22/07/2014

N/A

A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy - N/A

IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

Product Name: Fostamatinib 100 mg tablet
Product Code: R935788
INN or Proposed INN: Fostamatinib
Other descriptive name: FOSTAMATINIB DISODIUM
Product Name: Fostamatinib 150 mg tablet
Product Code: R935788
INN or Proposed INN: Fostamatinib
Other descriptive name: FOSTAMATINIB DISODIUM

Rigel Pharmaceuticals Inc

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Hong Kong;Taiwan;Singapore;Austria;United Kingdom;Switzerland